Wojewódzki Szpital Specjalistyczny nr 5 im. św. Barbary w Sosnowcu
- Address
- Pl. Medykow 1, 41-200 Sosnowiec, Poland
Wojewódzki Szpital Specjalistyczny nr 5 im. św. Barbary w Sosnowcu - Neuro-Oncology Research Center
This specialized medical facility demonstrates advanced expertise in neuro-oncology research, focusing on innovative treatment approaches for aggressive brain tumors. The center is actively engaged in cutting-edge immunotherapy research combined with standard therapeutic protocols for challenging neurological malignancies.
- Glioblastoma Multiforme (GBM) treatment optimization
- Neoadjuvant and adjuvant immunotherapy strategies
- Integration of Pembrolizumab with chemo-radiotherapy protocols
The research program emphasizes evaluating both short-term safety and long-term efficacy outcomes in patients with newly diagnosed glioblastoma. By combining Pembrolizumab immunotherapy with the established Stupp protocol (standard chemo-radiotherapy), the center is pioneering approaches to enhance treatment effectiveness for this aggressive brain cancer, contributing valuable data to the evolving landscape of neuro-oncological care.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 3 by active trials.
- 1Agencja Badań Medycznych3active
lock +2 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Agencja Badań Medycznych3trials
lock +1 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 1 624 other sites in Poland
Therapeutic Area Benchmark — Poland
Select a therapeutic area to compare against other sites in Poland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Poland
Market Share
Country: Poland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Wojewódzki Szpital Specjalistyczny nr 5 im. św. Barbary w Sosnowcu
lock Showing 1 of 4 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Efficacy and Safety of Infliximab, Tofacitinib, and Vedolizumab in Induction-Resistant Ulcerative Colitis: A Comparative Analysis | Agencja Badań Medycznych, Wojskowy Instytut Medyczny Panstwowy Instytut Badawczy | Phase II | Recruiting | May 2025 | — |
IMP list
lock Showing 1 of 6 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Infliximab | 2 | Unknown | 2025-04-18 | 2025-05-27 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.